Suppr超能文献

具有抗弓形虫活性的临床可用药物

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

作者信息

Neville Andrew J, Zach Sydney J, Wang Xiaofang, Larson Joshua J, Judge Abigail K, Davis Lisa A, Vennerstrom Jonathan L, Davis Paul H

机构信息

Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA.

College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.

出版信息

Antimicrob Agents Chemother. 2015 Dec;59(12):7161-9. doi: 10.1128/AAC.02009-15. Epub 2015 Sep 21.

Abstract

Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

摘要

刚地弓形虫是一种寄生于人类和包括家畜及伴侣动物在内的其他哺乳动物的顶复门寄生虫。虽然包括乙胺嘧啶和磺胺嘧啶方案在内的化疗方案可改善急性或复发疾病,如弓形虫性脑炎或眼弓形虫病,但这些药物通常对宿主有毒性。此外,目前尚无获批的治疗方案可用于治疗感染的孕妇。最后,尚无任何药物方案能够根除感染的慢性阶段,该阶段的特征是存在对化疗耐药的细胞内囊肿,会在宿主的生命周期内持续存在。为了推动更多化疗方案的出现,我们现在评估在疾病模型中已显示出疗效但缺乏临床病例报告的临床可用药物。理想情况下,可确定并开发出毒性较小的急性疾病治疗方法,另外一个目标是清除人类和动物宿主中的囊肿。

相似文献

1
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.
Antimicrob Agents Chemother. 2015 Dec;59(12):7161-9. doi: 10.1128/AAC.02009-15. Epub 2015 Sep 21.
3
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans.
PLoS One. 2015 Sep 22;10(9):e0138204. doi: 10.1371/journal.pone.0138204. eCollection 2015.
5
Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Exp Parasitol. 2013 Mar;133(3):294-9. doi: 10.1016/j.exppara.2012.12.011. Epub 2012 Dec 25.
6
Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
Curr Top Microbiol Immunol. 1996;219:235-45. doi: 10.1007/978-3-642-51014-4_21.
7
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
J Antimicrob Chemother. 1998 Nov;42(5):665-7. doi: 10.1093/jac/42.5.665.
9
Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Antimicrob Agents Chemother. 2004 Dec;48(12):4848-54. doi: 10.1128/AAC.48.12.4848-4854.2004.

引用本文的文献

2
Study of anti-Toxoplasma gondii effect of mPEG-PCL copolymeric loaded with pyrimethamine, in vitro.
AMB Express. 2025 May 2;15(1):69. doi: 10.1186/s13568-025-01876-8.
3
High-Throughput Repurposing Screen Reveals Compounds with Activity against Bradyzoites.
ACS Infect Dis. 2025 Mar 14;11(3):600-609. doi: 10.1021/acsinfecdis.4c00689. Epub 2025 Feb 11.
6
Lactoferrin-modified nanoemulsions enhance brain-targeting and therapeutic efficacy of arctigenin against Toxoplasma gondii-induced neuronal injury.
Int J Parasitol Drugs Drug Resist. 2025 Apr;27:100575. doi: 10.1016/j.ijpddr.2024.100575. Epub 2024 Dec 20.
7
High Throughput Repurposing Screen Reveals Compounds with Activity Against Bradyzoites.
bioRxiv. 2024 Aug 22:2024.07.01.601569. doi: 10.1101/2024.07.01.601569.
8
The Effects and Mechanism of ATM Kinase Inhibitors in .
Int J Mol Sci. 2024 Jun 25;25(13):6947. doi: 10.3390/ijms25136947.
9
Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat Model.
Biomedicines. 2024 Jun 11;12(6):1295. doi: 10.3390/biomedicines12061295.
10

本文引用的文献

1
Current Therapy of Acquired Ocular Toxoplasmosis: A Review.
J Ocul Pharmacol Ther. 2015 Nov;31(9):511-7. doi: 10.1089/jop.2015.0059. Epub 2015 Jul 30.
2
In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Jpn J Infect Dis. 2016;69(2):113-7. doi: 10.7883/yoken.JJID.2015.023. Epub 2015 Jul 10.
3
Could miltefosine be used as a therapy for toxoplasmosis?
Exp Parasitol. 2015 Oct;157:12-22. doi: 10.1016/j.exppara.2015.06.005. Epub 2015 Jun 23.
4
Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis.
Acta Psychiatr Scand. 2015 Sep;132(3):161-79. doi: 10.1111/acps.12423. Epub 2015 Apr 15.
5
A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria.
Nature. 2015 Apr 30;520(7549):683-7. doi: 10.1038/nature14412. Epub 2015 Apr 15.
6
Anti-Toxoplasma activity of natural products: a review.
Recent Pat Antiinfect Drug Discov. 2014;9(3):186-94. doi: 10.2174/1574891x10666150410120321.
8
Recent advances in Toxoplasma gondii immunotherapeutics.
Korean J Parasitol. 2014 Dec;52(6):581-93. doi: 10.3347/kjp.2014.52.6.581. Epub 2014 Dec 23.
9
Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis.
Exp Parasitol. 2015 Feb;149:54-64. doi: 10.1016/j.exppara.2014.12.007. Epub 2014 Dec 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验